Esther Rajavelu Sells 25,240 Shares of Spero Therapeutics (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) insider Esther Rajavelu sold 25,240 shares of Spero Therapeutics stock in a transaction on Monday, May 4th. The shares were sold at an average price of $2.51, for a total value of $63,352.40. Following the sale, the insider directly owned 986,851 shares of the company’s stock, valued at approximately $2,476,996.01. This trade represents a 2.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Esther Rajavelu also recently made the following trade(s):

• On Friday, February 6th, Esther Rajavelu sold 87,917 shares of Spero Therapeutics stock. The shares were sold at an average price of $2.36, for a total value of $207,484.12.

Spero Therapeutics Stock Down 0.8%

Shares of NASDAQ SPRO opened at $2.51 on Friday. The business has a fifty day simple moving average of $2.51 and a two-hundred day simple moving average of $2.41. The firm has a market cap of $145.33 million, a PE ratio of 20.92 and a beta of 1.43. Spero Therapeutics, Inc. has a twelve month low of $0.57 and a twelve month high of $3.22.

Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Thursday, March 26th. The company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.73. The business had revenue of $41.30 million during the quarter, compared to analyst estimates of $26.00 million. Spero Therapeutics had a return on equity of 22.53% and a net margin of 12.83%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Invesco Ltd. acquired a new position in Spero Therapeutics during the 2nd quarter valued at about $43,000. Millennium Management LLC acquired a new position in Spero Therapeutics during the 4th quarter valued at about $56,000. Dimensional Fund Advisors LP acquired a new position in Spero Therapeutics during the 3rd quarter valued at about $55,000. XTX Topco Ltd acquired a new position in Spero Therapeutics during the 2nd quarter valued at about $100,000. Finally, Quadrature Capital Ltd acquired a new position in Spero Therapeutics during the 4th quarter valued at about $88,000. 25.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on SPRO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen raised Spero Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Sunday, March 29th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce”.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.